{"filing":{"accession_number":"0001410098-26-000044","cik":"0001410098","ticker":"CRMD","company_name":"CorMedix Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"crmd-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/crmd-20260807.htm"},"events":[{"id":25065,"run_id":22738,"accession_number":"0001410098-26-000044","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"summary":"The filing discloses preliminary court approval of a settlement of consolidated shareholder derivative lawsuits against CorMedix and its officers/directors. The underlying claims allege breach of fiduciary duties related to false/misleading statements about manufacturing deficiencies that delayed FDA approval of DefenCath, resulting in a securities fraud class action and significant harm to the company. The settlement requires implementation of corporate governance reforms over 3.5 years, with potential attorneys' fees up to $3.9 million. This is a material litigation settlement with substantial corporate governance consequences.","company_name":"CorMedix Inc.","ticker":"CRMD","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":25805,"accession_number":"0001410098-26-000044","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses preliminary court approval of a settlement of consolidated shareholder derivative lawsuits against CorMedix and its officers/directors. The underlying claims allege breach of fiduciary duties related to false/misleading statements about manufacturing deficiencies that delayed FDA approval of DefenCath, resulting in a securities fraud class action and significant harm to the company. The settlement requires implementation of corporate governance reforms over 3.5 years, with potential attorneys' fees up to $3.9 million. This is a material litigation settlement with substantial corporate governance consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T00:19:38.081870+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25805,"accession_number":"0001410098-26-000044","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses preliminary court approval of a settlement of consolidated shareholder derivative lawsuits against CorMedix and its officers/directors. The underlying claims allege breach of fiduciary duties related to false/misleading statements about manufacturing deficiencies that delayed FDA approval of DefenCath, resulting in a securities fraud class action and significant harm to the company. The settlement requires implementation of corporate governance reforms over 3.5 years, with potential attorneys' fees up to $3.9 million. This is a material litigation settlement with substantial corporate governance consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T00:19:38.081870+00:00","company_name":"CorMedix Inc.","ticker":"CRMD","filing_date":"2026-08-07"}]}